198 related articles for article (PubMed ID: 37578236)
1. The La Crosse virus class II fusion glycoprotein
Thannickal SA; Spector SN; Stapleford KA
J Virol; 2023 Aug; 97(8):e0081923. PubMed ID: 37578236
[TBL] [Abstract][Full Text] [Related]
2. The La Crosse virus class II fusion glycoprotein
Thannickal SA; Spector SN; Stapleford KA
bioRxiv; 2023 Feb; ():. PubMed ID: 36865275
[TBL] [Abstract][Full Text] [Related]
3. Structurally Conserved Domains between Flavivirus and Alphavirus Fusion Glycoproteins Contribute to Replication and Infectious-Virion Production.
Rangel MV; Catanzaro N; Thannickal SA; Crotty KA; Noval MG; Johnson KEE; Ghedin E; Lazear HM; Stapleford KA
J Virol; 2022 Jan; 96(2):e0177421. PubMed ID: 34757841
[TBL] [Abstract][Full Text] [Related]
4. Targeted Mutations in the Fusion Peptide Region of La Crosse Virus Attenuate Neuroinvasion and Confer Protection against Encephalitis.
Hollidge BS; Salzano MV; Ibrahim JM; Fraser JW; Wagner V; Leitner NE; Weiss SR; Weber F; González-Scarano F; Soldan SS
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891445
[TBL] [Abstract][Full Text] [Related]
5. The chikungunya virus E1 glycoprotein fusion loop and hinge alter glycoprotein dynamics leading to cell and host specific changes in infectivity.
Thannickal SA; Battini L; Spector SN; Noval MG; Álvarez DE; Stapleford KA
bioRxiv; 2023 Nov; ():. PubMed ID: 37961096
[TBL] [Abstract][Full Text] [Related]
6. Novel Ionophores Active against La Crosse Virus Identified through Rapid Antiviral Screening.
Sandler ZJ; Firpo MR; Omoba OS; Vu MN; Menachery VD; Mounce BC
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32284379
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of infectivity of insect cell-derived La Crosse Virus by human serum.
Cruz MA; Parks GD
Virus Res; 2021 Jan; 292():198228. PubMed ID: 33188797
[TBL] [Abstract][Full Text] [Related]
8. La Crosse virus (LACV) Gc fusion peptide mutants have impaired growth and fusion phenotypes, but remain neurotoxic.
Soldan SS; Hollidge BS; Wagner V; Weber F; González-Scarano F
Virology; 2010 Sep; 404(2):139-47. PubMed ID: 20553924
[TBL] [Abstract][Full Text] [Related]
9. A recombinant chimeric La Crosse virus expressing the surface glycoproteins of Jamestown Canyon virus is immunogenic and protective against challenge with either parental virus in mice or monkeys.
Bennett RS; Gresko AK; Nelson JT; Murphy BR; Whitehead SS
J Virol; 2012 Jan; 86(1):420-6. PubMed ID: 22013033
[TBL] [Abstract][Full Text] [Related]
10. Mutagenesis of the La Crosse Virus glycoprotein supports a role for Gc (1066-1087) as the fusion peptide.
Plassmeyer ML; Soldan SS; Stachelek KM; Roth SM; Martín-García J; González-Scarano F
Virology; 2007 Feb; 358(2):273-82. PubMed ID: 17027056
[TBL] [Abstract][Full Text] [Related]
11. Impacts of climate, land use, and biological invasion on the ecology of immature Aedes mosquitoes: implications for La Crosse emergence.
Leisnham PT; Juliano SA
Ecohealth; 2012 Jun; 9(2):217-28. PubMed ID: 22692799
[TBL] [Abstract][Full Text] [Related]
12. Changes in the chikungunya virus E1 glycoprotein domain II and hinge influence E2 conformation, infectivity, and virus-receptor interactions.
Thannickal SA; Battini L; Spector SN; Noval MG; Álvarez DE; Stapleford KA
J Virol; 2024 Jun; ():e0067924. PubMed ID: 38842335
[TBL] [Abstract][Full Text] [Related]
13. Genome sequence analysis of La Crosse virus and in vitro and in vivo phenotypes.
Bennett RS; Ton DR; Hanson CT; Murphy BR; Whitehead SS
Virol J; 2007 May; 4():41. PubMed ID: 17488515
[TBL] [Abstract][Full Text] [Related]
14. La Crosse Virus in Aedes japonicus japonicus mosquitoes in the Appalachian Region, United States.
Harris MC; Dotseth EJ; Jackson BT; Zink SD; Marek PE; Kramer LD; Paulson SL; Hawley DM
Emerg Infect Dis; 2015 Apr; 21(4):646-9. PubMed ID: 25811131
[TBL] [Abstract][Full Text] [Related]
15. La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeys.
Bennett RS; Cress CM; Ward JM; Firestone CY; Murphy BR; Whitehead SS
Virol J; 2008 Feb; 5():25. PubMed ID: 18267012
[TBL] [Abstract][Full Text] [Related]
16. Skin muscle is the initial site of viral replication for arboviral bunyavirus infection.
Schneider CA; Leung JM; Valenzuela-Leon PC; Golviznina NA; Toso EA; Bosnakovski D; Kyba M; Calvo E; Peterson KE
Nat Commun; 2024 Feb; 15(1):1121. PubMed ID: 38321047
[TBL] [Abstract][Full Text] [Related]
17. Age-dependent myeloid dendritic cell responses mediate resistance to la crosse virus-induced neurological disease.
Taylor KG; Woods TA; Winkler CW; Carmody AB; Peterson KE
J Virol; 2014 Oct; 88(19):11070-9. PubMed ID: 25008929
[TBL] [Abstract][Full Text] [Related]
18. Elongin C Contributes to RNA Polymerase II Degradation by the Interferon Antagonist NSs of La Crosse Orthobunyavirus.
Schoen A; Lau S; Verbruggen P; Weber F
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941775
[TBL] [Abstract][Full Text] [Related]
19. Emerging Chikungunya Virus Variants at the E1-E1 Interglycoprotein Spike Interface Impact Virus Attachment and Inflammation.
Rangel MV; McAllister N; Dancel-Manning K; Noval MG; Silva LA; Stapleford KA
J Virol; 2022 Feb; 96(4):e0158621. PubMed ID: 34935436
[TBL] [Abstract][Full Text] [Related]
20. Two Conserved Phenylalanine Residues in the E1 Fusion Loop of Alphaviruses Are Essential for Viral Infectivity.
Lucas CJ; Davenport BJ; Carpentier KS; Tinega AN; Morrison TE
J Virol; 2022 May; 96(9):e0006422. PubMed ID: 35416719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
